Test Price
2,800 AED✅ Home Collection Available
G6PD Gene (Favism) Susceptibility Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced Next Generation Sequencing (NGS) genetic test delivers 99.9% diagnostic sensitivity for detecting pathogenic variants in the G6PD gene that cause Favism and drug-induced hemolytic anemia. The analysis provides definitive carrier identification and severity classification, surpassing the limitations of traditional enzyme activity assays. Comprehensive post-test genetic counseling is included to guide personalized risk management.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM–11 PM.
- Clinical Guidance: Complimentary telephonic post-test genetic counseling for result interpretation and family screening recommendations.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The G6PD Gene Susceptibility Test utilizes Next Generation Sequencing (NGS) on the Illumina platform to fully sequence the G6PD gene, identifying all known pathogenic variants with >99.9% accuracy. This molecular analysis provides definitive detection of hemizygous males, homozygous females, and heterozygous carriers, enabling precise risk stratification for Favism and drug-induced hemolytic reactions.
| Feature | Our Test (NGS) | Standard G6PD Enzyme Assay |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity for all known mutations | ~95%, falsely normal during acute hemolysis or reticulocytosis |
| Method | Next Generation Sequencing (Illumina platform, ISO 15189 validated) | Spectrophotometric enzyme activity measurement |
| Turnaround Time | 3 to 4 Weeks | 1 to 3 Days |
| Carrier Detection | Definitive identification of heterozygous carriers | May miss many female carriers |
| Clinical Impact | Direct mutation report enables personalized avoidance list & family screening | Activity-based, cannot differentiate between variant classes |
Physician Insight & Safety Protocols
“A genetic susceptibility result from NGS analysis provides definitive information about G6PD variant status, but it must always be interpreted alongside the patient’s clinical history and family pedigree. I guide individuals through understanding their carrier status, potential severity, and evidence-based strategies to prevent hemolytic triggers. My goal is to translate complex genomic data into actionable health decisions.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Alert & Pre-Test Advisory
Do not discontinue prescribed medication without consulting your doctor.
- Exclusion Criteria: Recent allogeneic bone marrow transplant within 12 months (donor DNA may interfere). Inability to provide informed consent (minors require legal guardian). Samples with insufficient DNA yield will require re-collection.
- Emergency Red Flags: If you experience sudden dark urine, jaundice, severe fatigue, or back pain after consuming fava beans or initiating new drugs (e.g., sulfonamides, primaquine), seek emergency care immediately. A normal enzyme activity result during acute hemolysis can be falsely reassuring; genetic testing provides the definitive molecular answer.
- Pre-Test Guidance: No fasting required. A brief genetic counseling session to draft a family pedigree chart is recommended prior to sample collection.
Patient FAQ & Clinical Guidance
1. Why choose the G6PD gene test over an enzyme activity test?
This NGS analysis sequences the entire G6PD gene, identifying all pathogenic variants with >99.9% accuracy. Enzyme activity tests can produce falsely normal results during acute hemolysis or in female heterozygotes, whereas genetic testing provides definitive carrier and severity classification.
2. Is any special preparation or fasting required before sample collection?
No special preparation is required. You may eat and drink normally, as DNA analysis is unaffected by recent meals, medications, or timing of sample collection. A brief genetic counseling session is recommended to map your family history, but this can be arranged after scheduling your appointment.
3. How will I receive my results and who will explain them to me?
Your comprehensive mutation report is delivered securely via our encrypted patient portal. Our complimentary telephonic post-test guidance connects you directly with a Consultant Medical Geneticist who will interpret your results, discuss implications for family members, and recommend personalized management strategies tailored to your specific G6PD variant.
4. Can this test determine if I am a carrier and at risk of passing the condition to my children?
Yes, the NGS analysis definitively identifies heterozygous carriers (common in females) with >99.9% accuracy. The report includes inheritance pattern information and recommendations for partner testing and reproductive genetic counseling if desired.
5. How is my genetic data protected under UAE law?
Your genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Results are shared only with you and your designated healthcare provider unless explicit written consent is provided.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of data protection and clinical governance. All genetic testing and patient data handling comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient consent is obtained through a standardized informed consent process that clearly outlines data usage, storage duration, and patient rights prior to sample collection.
Our laboratory is ISO 15189 accredited, ensuring that every stage of the testing process—from specimen handling to result reporting—meets rigorous international quality standards. Your genetic information remains strictly confidential and is accessible only to authorized clinical personnel involved in your care.
Clinical & Logistical Metadata
| Test Name | G6PD Gene (Favism) Susceptibility Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM–11 PM |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina Platform, ISO 15189 Validated |
| ICD-10-CM Code | D55.0, Z13.89 |
| LOINC Code | 96512-1 |
| DHA Facility License & Laboratory Address | DNA Labs UAE | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians